Alan G Nyitray1, Mihyun Chang1, Luisa L Villa2, Roberto J Carvalho da Silva3, Maria Luiza Baggio4, Martha Abrahamsen5, Mary Papenfuss5, Manuel Quiterio6, Jorge Salmerón7, Eduardo Lazcano-Ponce8, Anna R Giuliano5. 1. The University of Texas School of Public Health at Houston, Texas. 2. School of Medicine, University of São Paulo, School of Medical Sciences, Santa Casa de São Paulo. 3. Centro de Referência e Treinamento em DST/AIDS. 4. Center of Translational Oncology, Instituto do Câncer do Estado de São Paulo-ICESP, Brazil. 5. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 6. Instituto Nacional de Salud Pública. 7. Instituto Nacional de Salud Pública Instituto Mexicano del Seguro Social. 8. Instituto Nacional de Salud Pública, Cuernavaca, Mexico.
Abstract
BACKGROUND: Although human immunodeficiency virus (HIV)-negative men having sex with men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospective studies of genital HPV infection in this population are scarce. METHODS: HPV genotyping was conducted on genital samples from men (aged 18-70 years) from Brazil, Mexico, or the United States who provided specimens at 6-month intervals for up to 4 years. Eligibility criteria included no history of genital warts or HIV infection. Evaluable specimens were collected from 564 MSM and 3029 men having sex with women (MSW). Incidence and clearance estimates with 95% confidence intervals were calculated. RESULTS: The 12-month cumulative incidence of genital HPV was high in both MSM (25%; 95% confidence interval, 21%-30%) and MSW (21%; 20%-23%). After stratifying by city, MSM and MSW incidence rates were comparable, with 3 exceptions where MSM had higher incidence in ≥1 city: the group of quadrivalent vaccine types, HPV-45, and HPV-11. Median times to HPV-16 clearance were also comparable, with point estimates of >6 months for both MSM and MSW. CONCLUSIONS: Unlike with many other sexually transmitted infections, genital HPV natural history may be similar in HIV-negative MSM and MSW. Study periods of ≤6 months, however, may not be long enough to accurately measure the persistence of these infections in men.
BACKGROUND: Although human immunodeficiency virus (HIV)-negative men having sex with men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospective studies of genital HPV infection in this population are scarce. METHODS:HPV genotyping was conducted on genital samples from men (aged 18-70 years) from Brazil, Mexico, or the United States who provided specimens at 6-month intervals for up to 4 years. Eligibility criteria included no history of genital warts or HIV infection. Evaluable specimens were collected from 564 MSM and 3029 men having sex with women (MSW). Incidence and clearance estimates with 95% confidence intervals were calculated. RESULTS: The 12-month cumulative incidence of genital HPV was high in both MSM (25%; 95% confidence interval, 21%-30%) and MSW (21%; 20%-23%). After stratifying by city, MSM and MSW incidence rates were comparable, with 3 exceptions where MSM had higher incidence in ≥1 city: the group of quadrivalent vaccine types, HPV-45, and HPV-11. Median times to HPV-16 clearance were also comparable, with point estimates of >6 months for both MSM and MSW. CONCLUSIONS: Unlike with many other sexually transmitted infections, genital HPV natural history may be similar in HIV-negative MSM and MSW. Study periods of ≤6 months, however, may not be long enough to accurately measure the persistence of these infections in men.
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Dan'elle Smith; Martha Abrahamsen; Mary Papenfuss; Manuel Quiterio; Luisa L Villa; Anna R Giuliano Journal: Sex Transm Dis Date: 2011-10 Impact factor: 2.830
Authors: Sarah C Woodhall; Mark Jit; Chun Cai; Tina Ramsey; Sadique Zia; Simon Crouch; Yvonne Birks; Robert Newton; W John Edmunds; Charles J N Lacey Journal: Sex Transm Dis Date: 2009-08 Impact factor: 2.830
Authors: Ruth Gil-Prieto; Pablo Viguera Ester; Alejandro Álvaro-Meca; María San Martín Rodríguez; Ángel Gil De Miguel Journal: Hum Vaccin Immunother Date: 2012-02-01 Impact factor: 3.452
Authors: Anna R Giuliano; Ji-Hyun Lee; William Fulp; Luisa L Villa; Eduardo Lazcano; Mary R Papenfuss; Martha Abrahamsen; Jorge Salmeron; Gabriella M Anic; Dana E Rollison; Danelle Smith Journal: Lancet Date: 2011-02-28 Impact factor: 79.321
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Danélle Smith; Martha Abrahamsen; Mary Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2011-01-01 Impact factor: 5.226
Authors: Beibei Lu; Raphael P Viscidi; Yougui Wu; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-03 Impact factor: 4.254
Authors: Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey Journal: Proc Natl Acad Sci U S A Date: 2017-12-05 Impact factor: 11.205
Authors: Daniel C Beachler; Tim Waterboer; Christine M Pierce Campbell; Donna J Ingles; Krystle A Lang Kuhs; Alan G Nyitray; Allan Hildesheim; Michael Pawlita; Aimée R Kreimer; Anna R Giuliano Journal: Papillomavirus Res Date: 2016-07-28